Inhibition of DNA damage with the activation of gastric mucosal protection and gastric carcinogenesis
| Project/Area Number |
05671018
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Kyoto prefectural University of Medicine |
|---|
Principal Investigator |
YAMANE Tetsuro Kyoto prefectural University of Medicine, 医学部, 教授 (50166766)
|
|---|
| Project Period (FY) |
1993 – 1995
|
| Project Status |
Completed (Fiscal Year 1995)
|
| Budget Amount *help |
¥2,200,000 (Direct Cost: ¥2,200,000)
Fiscal Year 1995: ¥400,000 (Direct Cost: ¥400,000)
Fiscal Year 1994: ¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 1993: ¥1,000,000 (Direct Cost: ¥1,000,000)
|
|---|
| Keywords | Gastric mucosal protection / DNA damage / Chemoprevention / Gastric cancer / Cytoprotection / MNNG / ENNG / Rebamipide / 胃発癌抑制 |
|---|
| Research Abstract |
We hypothesized that gastric carcinogenesis may controlled by the balance of the host defense mechanism and offense by carcinogen like a mechansisms of gastric formation. We tested Rebamipide in ENNG-induced mouse duodenal carcinogenesis. ENNG was administered to the C57B1/6 mice at a concentration of 100 mg/L for 4 weeks. Then, the mice were given Rebamipide (20 or 50mg/kg) for 16 weeks. In the 16th week of the experiment, the mice were killed and the duodenum and stomach were resected. Duodenal tumors were examined by stereomicroscopy, and their incidence and size were recorded. The incidence of duodenal tumors in mice treated with ENNG,ENNG plus 20mg/kg Rebamipide and ENNG plus 50mg/kg Rebamipide was 66.7%, 58.1% and 45.2% respectively. The difference between the group treated with ENNG and the group treated with ENNG plus Rebamipide was not significant.
Male wistar rats were given MNNG at a concentration of 80 mg/L for 28 weeks. Rebamipide was administered. In the 48th week of the expriment, the glandular stomach was examined for macroscopic tumors and histological examination were recorded. The incidence of gastric carcinogenesis in the group treated with MNNG and MNNG plus 20mg/kg Rebamipide was 76.9% and 61.5%, respectively. The incidence between the both groups were not significantly different. In the histological study of gastric tumors, the incidence of carcinoma and adenoma in the MNNG and MNNG Plus Rebamipide treated group were 69.2% and 30.7% respectively. The defference between these groups were significant (p<0.05).
|
Report
(3 results)
Research Products
(24 results)
